Molecular abnormalities in pediatric barrett esophagus: Can we test for potential of neoplastic progression?

Pediatric and Developmental Pathology

Volumn 13, Issue 4, 2010, Pages 310-317

  Maltby, Edna L ^a   Dyson, Michael J ^a   Wheeler, Mark R ^a   Thomson, Mike ^a   Sethuraman, Chitra ^a   Cohen, Marta C ^a  

^a SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Fluorescence in situ hybridization (FISH); HER2 amplification, loss of p16; Pediatric barrett esophagus

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CENTROMERE; CHILD; CHILDHOOD DISEASE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 9P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; DE LANGE SYNDROME; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL REFLUX; GENETIC MARKER; HIATUS HERNIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SCHOOL CHILD; ADENOCARCINOMA; CHROMOSOME ABERRATION; DISEASE COURSE; ESOPHAGUS; ESOPHAGUS TUMOR; GENETICS; METHODOLOGY; PATHOLOGY; PRECANCER; PREDICTIVE VALUE;

ADENOCARCINOMA; ADOLESCENT; ADULT; BARRETT ESOPHAGUS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS;

EID: 79952063599     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/09-08-0700-OA.1     Document Type: Article

References (21)

1. Donaldson L. CMO annual report 2007. A pathological concern understanding the rise in oesophageal cancer. Available at http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/AnnualReports/DH-086176. Accessed July 29, 2009.
2. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. Available at http://www.bsg.org.uk. Accessed July 29, 2009.
3. Riegman PHJ, Vissers J, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61:3164-3170. (Pubitemid 32691970)
4. Di Pietro M, Fitzgerald RC. Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet 2009;126:233-246.
5. Fahmy M, Skacel M, Gramlich TL, et al. Chromosome gains and genomic loss of p53 and p16 genes in Barrett's oesophagus detected by fluorescence in situ hybridisation. Mod Pathol 2004;17:588-596. (Pubitemid 38868427)
6. Brankley SM, Wand KK, Harwood AR, et al. The development of a fluorescence in situ hybridisation assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diag 2006;8:260-267. (Pubitemid 43811251)
7. Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative scoring techniques. J Clin Pathol 2005;58:710-714. (Pubitemid 40956824)
8. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK; further update to recommendations. J Clin Pathol 2008;61:818-824. (Pubitemid 351969725)
9. Sanders DSA, Taniere P, Harrison RF, et al. Clinical and molecular pathology of the metaplasia-dysplasia-carcinoma sequence in Barrett's oesophagus. Curr Diagn Pathol 2003;9:235-241. (Pubitemid 36759397)
10. Cohen MC, Ashok D, Gell M, et al. Pediatric columnar lined esophagus (CLO) vs Barrett's esophagus: is it the time for a consensus definition? Pediatr Dev Pathol 2009;12:116-126.
11. Souza RF, Krishnan K, Spechler SJ. Acid, bile and CDX: the ABCs of making Barrett's metaplasia. Liver Physiol 2008;295:G211-G218.
12. Cohen MC, Vergani P, Vigovichn F, Taylor C, Thomson M, Hammond D. Investigation of molecular alterations of paediatric Barrett's oesophagus using laser microdissection on paraffinembedded endoscopic biopsies. J Pediatr Gastroenterol Nutr 2007;45:44-49. (Pubitemid 47012329)
13. McManus DT, Olaru A, Meltzer SJ. Biomarkers of espohageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-1569. (Pubitemid 38428671)
14. Barrett M, Sanchez CA, Galipeau PC. Allelic loss of 9p21 and mutation of the CDKN2/p16 green develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-1873. (Pubitemid 26397445)
15. Wong DJ, Paulson TG, Prevo JJ, et al. p16(INK4a) lesions are common early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;15: 8284-8289.
16. Hardie LJ, Darnton SJ, Wallis YL, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005;217:221-230. (Pubitemid 40023121)
17. Tischoff I, Tannepfel A. Barrett's esophagus: can biomarkers predict progression to malignancy? Expert Rev Gastroenterol Hepatol 2008;2:653-663.
18. Rossi E, Grisanti S, Villanacci V, et al. HER2 overexpression/ amplification in Barrett's esophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med 2009;13:3826-3833.
19. Rauser S, Weiss R, Brasselmann H, et al. Significance of HER2 low level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007;13:5115-5123. (Pubitemid 47502079)
20. Chak A, Ochs-Balcomb H, Falk G, et al. Familiarity in Barrett's Esophagus, adenocarcinoma of the esophagus and adenocarcinoma of the oesophageal junction. Cancer Epidemiol Biomarkers Prev 2006;15:1668-1673. (Pubitemid 44497103)
21. Rygiel AM, Milano F, Febo KJ, et al. Assessment of chromosomal gains compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes Chromosomes Cancer 2008;47:396-404. (Pubitemid 351451794)